TLR7 and neoplasm: Furthermore, combination therapy with TLR7 and TLR9 agonists 1V270 and SD-101(CpG) and immune checkpoint inhibitor (anti-PD1 mAbs) successfully induced tumor regression along with an increased ratio of M1-like to M2-like TAMs in murine models of head and neck squamous cell carcinoma [227].